Research In Focus
27 June 2024
MSWA is proud to announce a commitment of $5.6m to neurological research in the 2024/2025 financial year.
This includes our ongoing investment as the leading funder of the groundbreaking PLATYPUS clinical trial.
This world-leading clinical trial will seek to reverse neurological damage caused by primary progressive multiple sclerosis (PPMS) in Australians living with the debilitating condition.
The flexible nature of the multi-arm, multi-stage (MAMS) adaptive design will allow researchers to investigate the potential benefits of several existing medications simultaneously. This means unpromising treatment arms can be dropped and new treatments added, producing results much faster than traditional clinical trial methods.